Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
May 16 2023 - 4:00PM
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage
biotech company developing a new class of custom-built protein
drugs known as DARPin therapeutics, today announced that Patrick
Amstuts, Chief Executive Officer, will participate in the 2023 RBC
Capital Markets Global Healthcare Conference, in-person, May 16-17,
2023.
Details:
- Fireside chat – Wednesday, May 17, 2023,
at 2:05pm ET
A copy of the presentation, as well as a recording of the
fireside chat will be made available through the Molecular
Partners website.
About Molecular Partners AG Molecular
Partners AG is a clinical-stage biotech company developing DARPin
therapeutics, a new class of custom-built protein drugs designed to
address challenges current modalities cannot. The Company has
formed partnerships with leading pharmaceutical companies to
advance DARPin therapeutics in the areas of oncology and infectious
disease and has compounds in various stages of clinical and
preclinical development across multiple therapeutic
areas. www.molecularpartners.com ; Find us on Twitter
- @MolecularPrtnrs.
For further details, please contact:Seth Lewis,
SVP IR and Strategyseth.lewis@molecularpartners.comTel: +1 781 420
2361
Antonio Ligi, Head of CommunicationsZürich-Schlieren,
Switzerlandantonio.ligi@molecularpartners.com+41 44 755 57 53
Molecular Partners (NASDAQ:MOLN)
Historical Stock Chart
From Apr 2024 to May 2024
Molecular Partners (NASDAQ:MOLN)
Historical Stock Chart
From May 2023 to May 2024